SCARD Inc is a non-profit organization dedicated to advancing skin cancer research and improving this disease’s prevention, diagnosis, and treatment.
Our mission is “To collect, manage and analyse deidentified data regarding the management of skin malignancies, and to provide education and statistical feedback for health care professionals.”
By collaborating with leading researchers, medical professionals, and patient advocates, SCARD Inc is committed to making a real impact in the management of skin cancer.
SCARD Inc represents the next phase in the evolution of the Skin Cancer Audit and Research Database, also known as the SCARD Surgical Audit. The SCARD Surgical Audit was established in 2007 to support primary care practitioners in evaluating their performance and patient management for skin cancer treatment. With the launch of SCARD Inc, this database has expanded to become a non-profit organization dedicated to advancing skin cancer research and improving patient outcomes.
At SCARD Inc, we remain committed to improving skin cancer treatment through research and education. By promoting awareness about the importance of early detection and effective treatment of skin cancer, we aim to reduce the impact of this disease on individuals and communities worldwide. Our organisation works with diverse stakeholders, including medical professionals, technology specialists, and researchers, to develop innovative solutions and improve the quality of care for skin cancer patients.
The second publication utilizing SCARD was in the International Journal of Dermatology in a paper called “The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in Australia.”
DetailsUndertaking self-auditing is crucial for doctors in their practices for several reasons. Self-auditing refers to evaluating one’s work to ensure that it meets the required standards, and it involves reviewing medical records, patient care, and clinical outcomes.
DetailsThe first publication about SCARD was in the International Journal of Dermatology in a paper called “Measuring Performance in skin cancer practice: the SCARD Initiative.”
Details
